In recent days, the landscape of MDS cancer treatment has attracted renewed attention as several biotech firms pushed forward promising therapies, signaling a potential shift in how myelodysplastic syndromes (MDS) could be managed — especially for those with high unmet needs.
A key milestone arrived with the clearance of a global Phase 3 trial for lisaftoclax (also known as APG-2575), a BCL-2 inhibitor, for first-line therapy in higher-risk MDS (HR-MDS). The study, named GLORA-4, will evaluate lisaftoclax in combination with azacitidine. Regulators in both the US and Europe signed off on the trial protocol — a not-insignificant development, given that HR-MDS has lacked a novel targeted therapy for decades.
According to trial sponsors, earlier data hinted at a ~75% overall response rate and a tolerable safety profile when used alongside azacitidine. If these results hold up in the larger Phase 3 context, lisaftoclax may become the first global BCL-2–targeted option for newly diagnosed HR-MDS — potentially redefining first-line care.
At the same time, immunotherapy approaches are gaining traction in the MDS cancer space. A report from last week highlighted that a novel triple-therapy immunotherapy — leveraging the body’s innate immune responses — is being advanced by GT Biopharma, Inc.. Their candidate, GTB-3650, is currently undergoing a Phase 1 trial targeting relapsed or refractory blood cancers, including high-risk MDS. Early dosing cohorts (Cohorts 1–3) reportedly showed acceptable safety, allowing escalation to a higher dose group.
Company statements suggest the next dosing stage (Cohort 4) could unlock the threshold for clinical efficacy, potentially paving the way toward a breakthrough if antitumor responses emerge.
Meanwhile, advocacy and investor attention is also coalescing around another front: established therapies for lower-risk MDS (LR-MDS). With anemia and transfusion dependence remaining a major burden for many patients, there is renewed interest in treatments that can reduce transfusion needs or improve bone marrow function.
At the upcoming American Society of Hematology Annual Meeting 2025 (ASH 2025), late-stage data on agents such as elritercept — an investigational activin inhibitor — will be presented. Elritercept has shown durable hematologic improvements in LR-MDS patients dependent on red blood cell transfusions.
Together, these developments suggest a broadening pipeline: from first-line targeted treatment for high-risk disease (lisaftoclax), to experimental immunotherapy for refractory MDS (GTB-3650), to novel supportive care for anemia in lower-risk cases (elritercept).
For patients and clinicians, this represents more than incremental progress — it signals a potential paradigm shift. While hypomethylating agents (HMA) and stem-cell transplantation have long served as the backbone of MDS cancer therapy, these emerging options could offer alternatives that are safer, more tolerable, and more specifically tailored to disease biology.
That said, key challenges remain: Phase 3 trials must confirm not just response rates but durability, quality-of-life benefit, and long-term safety. For immunotherapy candidates like GTB-3650, the balance between efficacy and immune-related toxicity will be critical. For agents targeting lower-risk MDS, achieving sustained transfusion independence without compromising marrow function remains a high bar.
Nevertheless, the momentum across multiple therapeutic classes — targeted small molecules, immunotherapies, and supportive agents — makes it clear: MDS cancer is no longer quietly stagnating. The coming 12–24 months may well bring the most substantial shift in treatment options for decades.
Related topic：
